Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 1:14 PM

ribavirin

Type: Keyphrase
Name: ribavirin
First Reported 11/19/2009 - Updated 11/20/2009 - 3 Documents (in Health)
Adamas Pharmaceuticals Expands Clinical Study for Triple-Combination Antiviral Drug Therapy in Immune-Compromised Patients
Study Finds Boosting Neurotransmitter Could Reverse Down Syndrome(10 hrs ago)Separated Bangladeshi Twins Expected to Make Full Recovery: Doctors(10 hrs ago)Alzheimer's Patients Receive Poor Care in Hospitals(13 hrs ago)School Dinners are the Only Meal ... [MedIndia - 11/20/2009]
First Reported 17 hours ago - Updated 17 hours ago - 1 Documents (in Health)
Study of PEG-rIL-29 Administered in Combination with Ribavirin for Untreated Hepatitis C Patients
Related ContentHealth ArticlesUnderstanding Clinical Trials : A participants' guideIn This SectionRelated Clinical TrialsThe purpose of this study is to test the safety and effectiveness of different doses of PEG-rIL-29 when given with the standard dose ... [DukeHealth.org - 17 hours ago]
First Reported 11/17/2009 - Updated 11/18/2009 - 3 Documents
InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection
InterMune, Inc. (Nasdaq: ITMN) today announced that the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of care (SOC) PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(R) (ribavirin) in HCV treatment-naive patients ... [Individual.com - 11/18/2009]
First Reported 11/18/2009 - Updated 11/18/2009 - 2 Documents (in Health)
Cyplasin Biomedical Ltd., and Virionics Corporation, announces Letter of Intent (LOI) for Reverse Takeover (RTO), Name Change and Related Financings
HOME NEWS PERSONAL FINANCE FINANCIAL TOOLS RATES PORTFOLIO COMPANY PROFILES SECTORS COLUMNISTS INDICES RRSP Centre Used Vehicles Classified Home >> Press Releases CPBM: OTCBB /CNW/ - Cyplasin Biomedical Ltd., announced today that it has entered ... [Canoe Money - 11/18/2009]
First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents (in Health)
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of...
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)2009 NOV 16 - (NewsRx.com) Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical ... [Pharmacy Choice - 11/16/2009]
First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Medicine)
UPDATE 1-InterMune to modify hep C study to drop one dosage
* Says data from 12-week treatment expected in Q1 2010 * Shares drop 16 pct Nov 17 (Reuters) - Biotechnology company InterMune Inc said it would discontinue one dosage in a mid-stage study testing its experimental therapy to treat hepatitis C, sending ... [Interactive Investor International - 11/17/2009]
First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents (in Health)
Oral HCV Protease Inhibitor R7227 plus Polymerase Inhibitor R7128 Suppresses HCV Viral Load without Interferon or Ribavirin
SUMMARY: Combination hepatitis C treatment using the nucleoside analog hepatitis C virus (HCV) polymerase inhibitor RG7128 (formerly R7128) plus the HCV NS3/4A protease inhibitor RG7227 (formerly R7227, also known as ITMN-191) produced potent antiviral ... [HIV and Hepatitis.com - 11/18/2009]
First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents (in Health)
Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients
Due to overlapping routes of transmission, many people are coinfected with both hepatitis B and C, a combination that increases the risk of liver disease progression. Researchers from Taiwan previously found that HBV/HCV coinfected patients had a relatively ... [HIV and Hepatitis.com - 11/18/2009]
First Reported 11/03/2009 - Updated 11/03/2009 - 4 Documents (in Health)
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG722
BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) and Pharmasset, Inc. (Nasdaq: VRUS) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds ... [Yahoo! Canada - 11/03/2009]
First Reported 11/01/2009 - Updated 11/02/2009 - 5 Documents (in Health)
UPDATE 1-Once-daily Schering hepatitis C drug shows promise
The pill, narlaprevir, is the first once-a-day member of an emerging new class of treatments for hepatitis C called protease inhibitors. They prevent replication of hepatitis C, a virus that can badly harm the liver for decades before symptoms develop ... [Interactive Investor International - 11/02/2009]
First Reported 11/02/2009 - Updated 11/03/2009 - 4 Documents (in Health)
AASLD: Once-Daily HCV Protease Inhibitors Show Early Promise
BOSTON -- Two investigational drugs targeting the hepatitis C virus (HCV) protease enzyme helped patients clear the virus with once-daily dosing, contrasting with the three-times-per-day schedule needed for similar drugs in development, researchers reported ... [MedPage Today - 11/03/2009]
First Reported 11/02/2009 - Updated 11/02/2009 - 3 Documents (in Medicine)
BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients
Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) p ... [News-Medical.Net - 11/02/2009]

Quotes

...Medical Microbiology, Academic Medical Centre of the University of Amsterdam, and Chair of the Protocol Steering Committee for this Phase 2 trial. "Based on preclinical results showing that Adamas' triple combination of amantadine, ribavirin, and oseltamivir is synergistic in its ability to block replication of the influenza virus, I believe Adamas' approach has much potential, and look forward to being involved in this study."
Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A [News-Medical.Net - 11/19/2009]
...' They continued, "The high rates of HBsAg clearance -- the closest outcome to cure in chronic hepatitis B -- coupled with the similar sustained virologic response rates in HCV/HBV coinfection compared with HCV monoinfection, suggests that peginterferon alfa-2a and ribavirin combination therapy is an effective first-line treatment strategy for this patient group." National Taiwan University College of Medicine, Taipei, Taiwan; Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Chang Gung Memorial Hospit...
Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infect ... [HIV and Hepatitis.com - 11/18/2009]
Kwo P, et al "High sustained virologic response (SVR) in genotype 1 (G1) null responders to peg-interferon alfa-2b (P) plus ribavirin (R) when treated with boceprevir (Boc) combination therapy" Hepatology 2009; 50: 331A-332A
AASLD: New Drug Boceprevir Boosts HCV Clearance for Nonresponders [National AIDS Treatment Advocacy Project - 11/11/2009]

More Content

All (282) | News (241) | Reports (14) | Blogs (8) | Audio/Video (0) | Fact Sheets (1)
sort by: Date | Relevance
Study of PEG-rIL-29 Administered in Combination... [DukeHealth.org - 17 hours ago]
Adamas Expands Triple-Combo Flu Trial [Pharmaceutical Technology - 11/20/2009]
Adamas Pharmaceuticals Expands Clinical Study f... [MedIndia - 11/20/2009]
Adamas Pharmaceuticals expands its Phase 2 TCAD... [News-Medical.Net - 11/19/2009]
Adamas Pharmaceuticals Expands Clinical Study f... [Street Insider - 11/19/2009]
Cyplasin Biomedical Ltd., and Virionics Corpora... [Canoe Money - 11/18/2009]
Cyplasin Biomedical Ltd., and Virionics Corpora... [Globe Investor - 11/18/2009]
Glitch in InterMune's HCV Trial; Toxicity Worri... [BioWorld - 11/18/2009]
InterMune Announces Modification to On-Going Ph... [Individual.com - 11/18/2009]
Pegylated Interferon plus Ribavirin Can Effecti... [HIV and Hepatitis.com - 11/18/2009]
Oral HCV Protease Inhibitor R7227 plus Polymera... [HIV and Hepatitis.com - 11/18/2009]
Morning Movers 11/17: ZOOM, SMTL, AGO, ABCW, XJ... [Street Insider - 11/17/2009]
UPDATE 1-InterMune to modify hep C study to dro... [Interactive Investor International - 11/17/2009]
InterMune (ITMN) Modifies On-Going Phase 2b Stu... [Street Insider - 11/17/2009]
InterMune Announces Modification to On-Going Ph... [Street Insider - 11/17/2009]
InterMune Announces Modification to On-Going Ph... [Yahoo! Canada - 11/17/2009]
Idenix Pharmaceuticals Initiates Phase II Clini... [Pharmacy Choice - 11/16/2009]
Stocks That Stand Out For Nov. 13th, 2009 Are H... [Pharmacy Choice - 11/14/2009]
Avanir Pharmaceuticals unveils Star trial resul... [News-Medical.Net - 11/12/2009]
SciClone Pharmaceuticals Announces Presentation... [Market Wire via MSN Money - 11/12/2009]
SciClone Pharmaceuticals Announces Presentation... [Stockwatch - 11/12/2009]
BMS Shells Out $85M Up Front for Alder’s... [Genetic Engineering News - 11/11/2009]
AASLD: New Drug Boceprevir Boosts HCV Clearance... [National AIDS Treatment Advocacy Project - 11/11/2009]
HCV Protease Inhibitor Telaprevir Demonstrates ... [HIV and Hepatitis.com - 11/10/2009]
Boosted Narlaprevir plus Pegylated Interferon a... [HIV and Hepatitis.com - 11/10/2009]
Nitazoxanide plus Pegylated Interferon and Riba... [HIV and Hepatitis.com - 11/10/2009]
Rapid Liver Fibrosis Progression and Successful... [HIV and Hepatitis.com - 11/10/2009]
InterMune, Inc. Q3 2009 Earnings Call Transcript [Seeking Alpha - 11/10/2009]
Studies to test steroids, statins for H1N1 [Centre For Infectious Disease Research and Policy - 11/10/2009]
Nov 8 Canadian Press story [Centre For Infectious Disease Research and Policy - 11/10/2009]
1 2 3 4 5 6 7 8 9
In Focus
  •  
PHASE 2, Henry Ford, Brian Daniels, [more]
  •  
Schering Plough Corporation, ZymoGenetics Incorporated, InterMune Incorporated, [more]
  •  
American Association for the Study of ..., Food and Drug Administration, University of Alabama at Birmingham, [more]
  •  
Hepatitis C, Interferon, Genotype, [more]
  •  
Boston (Massachusetts, United States), Osaka, Taipei, [more]
  •  
Japan, United States, Taiwan, [more]
  •  
Medication, Medicine, Biology, [more]
  •  
Pharma & Biotech, Health, IT, [more]
NEJM — Collection Updates for Viral ..., NEJM — Collection Updates for Liver ..., HIV and Hepatitis.com, [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Antiviral cocktail shows promise against resist... [H5N1 - 10/28/2009]
Via Medical News Today.com: Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1. Excerpt:An experimental drug cocktail that includes three prescriptions ...
FDA Calendar Updates: Anadys, Merck, Schering-P... [Healthcare Sector and Stocks Analysis from Seek ... - 07/31/2009]
Mike Havrilla submits:Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 289 entries as of 7/30/09. The calendar was ...
World Hepatitis Day: Prospects for the Future -... [Public Library of Science - PLoS Medicine - 05/19/2009]
"World Hepatitis Day...does not usually make the headlines in the same way that World AIDS day does, but viral hepatitis affects about half a billion people globally ...
World Hepatitis Day: Prospects for the Future -... [Public Library of Science blogs - 05/19/2009]
"World Hepatitis Day...does not usually make the headlines in the same way that World AIDS day does, but viral hepatitis affects about half a billion people globally ...
Guest blog by Paul Klenerman and colleagues: Wo... [Public Library of Science - PLoS Medicine - 05/19/2009]
"World Hepatitis Day...does not usually make the headlines in the same way that World AIDS day does, but viral hepatitis affects about half a billion people globally ...
1 2

  •  
  •  
  •